PartnershipJul 2, 2026, 07:11 AM
Arcturus Partners Thermo Fisher for ARCT-032 Development & Manufacturing
AI Summary
Arcturus Therapeutics has entered into a strategic collaboration with Thermo Fisher Scientific for the development and manufacturing of ARCT-032, its investigational mRNA therapeutic for cystic fibrosis. Under the Master Services Agreement, Thermo Fisher will provide up to $40 million in clinical manufacturing services, while Arcturus will engage Thermo Fisher's PPD for up to $40 million in CRO services. This partnership aims to support Phase 3 development and potential commercialization, with Thermo Fisher gaining exclusive commercial manufacturing rights upon regulatory approval.
Key Highlights
- Strategic collaboration with Thermo Fisher Scientific for ARCT-032 development.
- Thermo Fisher to contribute up to $40 million in clinical manufacturing services.
- Arcturus to engage PPD for up to $40 million in CRO services.
- Thermo Fisher gains exclusive commercial manufacturing rights upon regulatory approval.
- Master Services Agreement has an initial term of five years.
- Collaboration supports Phase 3 development and potential commercialization of ARCT-032.
Price Impact
More from ARCT